Despite its frequent expression at both mRNA and protein levels, the lack of correlation between PRAME protein expression and clinical outcomes in ovarian cancer highlights the complexity of its role, emphasizing the necessity for further studies to optimize therapeutic approaches and validate PRAME as a key molecule in targeted ovarian cancer therapy [74, 75]. This evidence concerns the gene PRAME and ovarian carcinoma.